54 Chapter 2 65. Simo M, Vaquero L, Ripolles P, et al. Brain damage following prophylactic cranial irradiation in lung cancer survivors. Brain Imaging Behav 2016; 10: 283–295. 66. Brown PD, Ballman K V., Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncology 2017; 118: 1049–1060. 67. El Shafie RA, Paul A, Bernhardt D, et al. Evaluation of Stereotactic Radiotherapy of the Resection Cavity After Surgery of Brain Metastases Compared to Postoperative Whole-Brain Radiotherapy (ESTRON)-A Single-Center Prospective Randomized Trial. Neurosurgery 2018; 83: 566–573. 68. El Shafie RA, Paul A, Bernhardt D, et al. Robotic Radiosurgery for Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence (CYBERSPACE)-A Single-Center Prospective Randomized Trial. Neurosurgery 2019; 84: 253–260. 69. Grosu A, Frings L, Bentsalo I, et al. Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) – a phase II prospective randomized multicenter trial (NOA-14, ARO 2015–3, DKTK-ROG). BMC Cancer 2020; 20: 1–13. 70. Schimmel WCM, Verhaak E, Hanssens PEJ, et al. A randomised trial to compare cognitive outcome after gamma knife radiosurgery versus whole brain radiation therapy in patients with multiple brain metastases: Research protocol CARstudy B. BMC Cancer 2018; 18: 218. 71. Wefel JS, Vardy J, Ahles T, et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12: 703–708. 72. Wilke C, Grosshans D, Duman J, et al. Radiation-induced cognitive toxicity: Pathophysiology and interventions to reduce toxicity in adults. Neuro Oncol 2018; 20: 597–607. 73. Rick O, Dauelsberg T, Kalusche-Bontemps EM. Oncological Rehabilitation. Oncol Res Treat 2017; 40: 772–777. 74. Tsai PF, Yang CC, Chuang CC, et al. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: A prospective study. Radiation Oncology 2015; 10: 253. 75. Lin S-Y, Yang C-C, Wu Y-M, et al. Evaluating the impact of hippocampal sparing during whole brain radiotherapy on neurocognitive functions: A preliminary report of a prospective phase II study. Biomed J 2015; 38: 439–449. 76. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013; 15: 1429–1437. 77. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non-Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial. Int J Radiat Oncol Biol Phys 2009; 73: 1069–1076. 78. Belderbos J, de Ruysscher D, de Jaeger K, et al. Phase III Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC. SSRN Electronic Journal. Epub ahead of print 2020. DOI: 10.2139/ ssrn.3708322. 79. Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III trial NRG oncology CC001. Journal of Clinical Oncology 2020; 38: 1019–1029.
RkJQdWJsaXNoZXIy MTk4NDMw